PE20231942A1 - Formulaciones inyectables de accion prolongada de sales de pamoato de ketamina - Google Patents

Formulaciones inyectables de accion prolongada de sales de pamoato de ketamina

Info

Publication number
PE20231942A1
PE20231942A1 PE2022000484A PE2022000484A PE20231942A1 PE 20231942 A1 PE20231942 A1 PE 20231942A1 PE 2022000484 A PE2022000484 A PE 2022000484A PE 2022000484 A PE2022000484 A PE 2022000484A PE 20231942 A1 PE20231942 A1 PE 20231942A1
Authority
PE
Peru
Prior art keywords
ketamine
pamoate salt
ketamine pamoate
salt
long
Prior art date
Application number
PE2022000484A
Other languages
English (en)
Inventor
Tong-Ho Lin
Yung-Shun Wen
Chia-Hsien Chen
Ying-Ting Liu
rui-zhi Hou
zhi-rong Wu
Original Assignee
Alar Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alar Pharmaceuticals Inc filed Critical Alar Pharmaceuticals Inc
Publication of PE20231942A1 publication Critical patent/PE20231942A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion se refiere a una composicion farmaceutica de liberacion sostenida que comprende 1 % p/p a 99% p/p de una forma cristalina o amorfa de una sal de pamoato de ketamina y un portador farmaceuticamente aceptable de la misma, en donde la sal de pamoato de ketamina se selecciona del grupo que consiste en sal de pamoato de R, S-ketamina, sal de pamoato de S-ketamina, sal de pamoato de R-ketamina y cualquier combinacion de los mismos, en donde la sal de pamoato de ketamina tiene una estequiometria de 2:1 o 1:1 de ketamina a pamoato, o una combinacion de los mismos. La forma cristalina de la sal de pamoato de ketamina se representa mediante un patron de difraccion de rayos X en polvo (XRPD) que comprende uno o mas valores de 2-theta seleccionados de 6.0, 10.7, 11.6, 12.0, 13.0, 14.7, 15.0, 22.2, 25.2 y 30.0 (+/- 0.2 2-theta). Las composiciones incluyen suspension acuosa inyectable, solucion inyectable y sistema de administracion de matriz, que pueden proporcionar una liberacion sostenida para anestesia, analgesia o tratamiento del sistema nervioso central y enfermedades antiinflamatorias.
PE2022000484A 2019-12-20 2020-12-18 Formulaciones inyectables de accion prolongada de sales de pamoato de ketamina PE20231942A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962951061P 2019-12-20 2019-12-20
PCT/CN2020/137496 WO2021121366A1 (en) 2019-12-20 2020-12-18 Long-acting injectable formulations of ketamine pamoate salts

Publications (1)

Publication Number Publication Date
PE20231942A1 true PE20231942A1 (es) 2023-12-05

Family

ID=76478186

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022000484A PE20231942A1 (es) 2019-12-20 2020-12-18 Formulaciones inyectables de accion prolongada de sales de pamoato de ketamina

Country Status (16)

Country Link
US (1) US20240099994A1 (es)
EP (1) EP4076410A4 (es)
JP (1) JP2023505963A (es)
KR (1) KR20220118427A (es)
CN (1) CN114340603B (es)
AR (1) AR120816A1 (es)
AU (1) AU2020410549A1 (es)
BR (1) BR112022012255A2 (es)
CA (1) CA3152593A1 (es)
CL (1) CL2022001636A1 (es)
CO (1) CO2022003543A2 (es)
IL (1) IL294089A (es)
MX (1) MX2022006596A (es)
PE (1) PE20231942A1 (es)
TW (1) TW202135782A (es)
WO (1) WO2021121366A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3753557A4 (en) 2018-02-15 2021-12-01 National University Corporation Chiba University PREVENTIVE OR THERAPEUTIC AGENT AND PHARMACEUTICAL COMPOSITION FOR INFLAMMATORY DISEASES OR BONE DISEASES
JP2021523228A (ja) 2018-05-04 2021-09-02 パーセプション ニューロサイエンス，インコーポレイティド 物質乱用の治療方法
WO2023178039A1 (en) * 2022-03-14 2023-09-21 Perception Neuroscience, Inc. Pharmaceutical formulations of r-ketamine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080293695A1 (en) * 2007-05-22 2008-11-27 David William Bristol Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance
CN116251084A (zh) * 2013-03-15 2023-06-13 詹森药业有限公司 S-盐酸氯胺酮的药物组合物
AU2017351437B2 (en) * 2016-10-27 2022-01-27 National University Corporation Chiba University Application of (S)-norketamine and salt thereof as pharmaceutical
IL290150B2 (en) * 2016-12-26 2024-03-01 Cellix Bio Private Ltd Compounds and methods for treating chronic pain
US10441544B2 (en) * 2017-10-10 2019-10-15 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
CA3077645A1 (en) * 2017-10-10 2019-04-18 Douglas Pharmaceuticals Ltd. A solid extended-release pharmaceutical formulations comprising ketamine or norketamine
WO2019172920A1 (en) * 2018-03-09 2019-09-12 Rk Pharmaceuticals, Llc Injectable composition for controlled-release of active ingredient to manage postoperative pain or neuropathic back pain
EP3761970A4 (en) * 2018-03-26 2022-06-08 Cellix Bio Private Limited COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES
CA3118954A1 (en) * 2019-01-11 2020-07-16 Alar Pharmaceuticals Inc. Ketamine pamoate and use thereof

Also Published As

Publication number Publication date
CN114340603B (zh) 2024-06-07
CL2022001636A1 (es) 2023-01-27
AU2020410549A1 (en) 2022-04-14
EP4076410A4 (en) 2024-02-07
US20240099994A1 (en) 2024-03-28
IL294089A (en) 2022-08-01
EP4076410A1 (en) 2022-10-26
CA3152593A1 (en) 2021-06-24
WO2021121366A1 (en) 2021-06-24
CO2022003543A2 (es) 2022-04-19
CN114340603A (zh) 2022-04-12
BR112022012255A2 (pt) 2022-08-30
TW202135782A (zh) 2021-10-01
AR120816A1 (es) 2022-03-23
KR20220118427A (ko) 2022-08-25
MX2022006596A (es) 2022-07-05
JP2023505963A (ja) 2023-02-14

Similar Documents

Publication Publication Date Title
PE20231942A1 (es) Formulaciones inyectables de accion prolongada de sales de pamoato de ketamina
ES2669793T3 (es) Derivados de 2-quinolinil-ácido acético como compuestos antivirales del VIH
UY30411A1 (es) Derivados sustituidos del acetato de 2,3,4,-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones
UY37007A (es) Compuestos derivados de purinas, estimuladores de genes de interferón
EA201992601A1 (ru) Конденсированное имидазопиперидиновое соединение, являющееся ингибитором jak
ES2541689T3 (es) Métodos para tratar trastornos resistentes a metotrexato con 10-propargil-2-desazaaminopterina
AR083849A1 (es) Antagonistas de mdm2 de espiro-oxindol
CO6670589A2 (es) Compuestos para reducir la producción de beta-amiloide
CL2020001343A1 (es) Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson.
PA8547701A1 (es) Nucleosidos 4 substituidos.
CU20200053A7 (es) Compuesto de pirimidina como inhibidor de las janocinasas, composición, forma cristalina y proceso de preparación
AR116116A1 (es) Proceso para elaborar inhibidores de jak e intermediarios de los mismos
AR044856A1 (es) Acidos biariloximetilarenocarboxilicos; procedimientos para su preparacion; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos.
BR112015023705A2 (pt) composto da fórmula (ia) ou um sal, hidrato, solvato ou forma cristalina farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composto e método para síntese do composto da fórmula (ia)
AR072233A1 (es) Derivados de acido lipoico y composiciones farmaceuticas que los contienen y metodos para tratar una enfermedad
CO2024001367A2 (es) Compuestos antivirales
JP2019532067A5 (es)
BR0309990A (pt) Processo para produzir um hidrato de um sal de adição de ácido de um composto, hidrato de um sal de adição de ácido de um composto, composição farmacêutica ou veterinária, uso de um hidrato agente para o uso como um inibidor ou p-glicoproteìna, e, métodos para modular a mdr modulada pela p-gp no tratamento de tumores, para potencializar a citotoxicidade de um agente citotóxico para uma célula de tumor, para tratar uma doença em que o patógeno responsável exibe resistência a múltiplos medicamentos, e para realçar uma caracterìstica de um agente terapêutico
CO2021014210A2 (es) Compuestos de pirrol
NI202100012A (es) Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6
PE20230601A1 (es) Pirrolopirimidinaminas como inhibidores del sistema del complemento
EA201000120A1 (ru) Фармацевтические композиции, содержащие холиновые соли янтарной кислоты, для интраназального введения
ECSP045373A (es) Sales de tolterodina
PE20160284A1 (es) Derivados de amida como antogonistas del receptor de acido lisofosfatidico
UY39181A (es) COMPUESTOS Y COMPOSICIONES PARA INHIBIR LA ACTIVIDAD DE HIF2a Y SUS MÉTODOS DE USO